The case for & against
Bull & Bear analysis
Bullish
Quipt Home Medical Corp. (QIPT) is a healthcare services company specializing in home medical equipment and services, with a significant focus on respiratory care, which constitutes approximately 77-80% of its product offerings. Positioned in the durable medical equipment (DME) market, Quipt aims to capitalize on the growing demand for home-based healthcare solutions driven by the aging population and increased chronic respiratory diseases. Despite recent challenges, Quipt maintains strong partnerships with healthcare systems, enhancing its ability to deliver integrated care services.
Bull says
- ↑Q4 2024 revenue hit $245.9M, up 16% YoY, with recurring sales at 81% of total
- ↑Adjusted EBITDA margin rose to 23.5%, reflecting strong operational efficiency
- ↑Joint venture with Heart Medical Equipment expands Midwest referral network
- ↑GLP-1 therapy adoption boosts sleep-apnea therapy starts by ~10.8%
- ↑Net debt/EBITDA at 1.5x supports investment flexibility
- ↑Aging population and rising chronic respiratory cases underpin long-term growth
Bear says
- ↓Q2 2025 revenue declined 6% YoY due to Medicare 7525 rate cut, creating an $8M drag
- ↓Operating expenses jumped to 50.8% of revenue, eroding profitability
- ↓Patient attrition from lost contracts disrupted setup deliveries and growth
- ↓Bad debt from prior cybersecurity incident hinders cash flow recovery
- ↓Civil Investigative Demand (CID) raises regulatory compliance and penalty risks
- ↓Heavy reliance on Medicare reimbursement exposes QIPT to regulatory headwinds
Investment themes with QIPT
Demographics: Elderly Care↑ +0.43%
Services and products for aging population
ENSG · ACHC · SEM
Earnings Call · Q3 2025 · Mgmt. Guidance
Updated 05-09-2026bullish
Transcript signals
Bull points
- This quarter marks a return to positive organic growth and signals clear revenue stabilization across our business.
- Revenue for fiscal Q3 2025 came in at 58.3 million compared to 60.8 million in Q3 2024, a decrease of only 4.1% compared to the prior year.
- Recurring revenue for Q3 2025 continues to be strong at 81% of total revenue.
Bear points
- The company's customer base decreased modestly serving 151,000 unique patients as of June 30, 2025, compared to 153,000 unique patients as of June 30, 2024.
- The company reported $11.3 million of cash on hand as of June 30, 2025, as compared to $17.1 million of cash on hand as of March 31, 2025.
- Operating expenses as a percentage of revenue came in at 53.3% in Q3, 2025 compared to 50.4% in the corresponding period in 2024.
Read full transcript analysis ›